This invention provides compounds of Formula I having the structure: ##STR00001## wherein: B is alkyl of 1-4 carbons or alkoxy of 1-4 carbons; R.sub.1 is aryl or Het optionally substituted with R.sub.6; R.sub.2 and R.sub.3 are each independently, alkyl of 1-4 carbons, CF.sub.3, aryl or Het substituted with R.sub.6, or R.sub.2 and R.sub.3 are combined to form a cycloalkyl or heterocyclic ring optionally substituted with alkyl, benzyl, or acyl; R.sub.4, and R.sub.5 are each independently, hydrogen, halogen, alkyl of 1-4 carbons, CO.sub.2R.sub.7, SO.sub.2NHR.sub.7, CONHR.sub.7, CN, NO.sub.2 or CF.sub.3; R.sub.6 is hydrogen, halogen, NO.sub.2, alkyl of 1-4 carbons, alkoxy of 1-4 carbons, alkylcarbonyloxy of 2-7 carbon atoms, alkylcarbonyl of 2-7 carbon atoms, CF.sub.3, or COOH; and R.sub.7 is hydrogen, alkyl of 1-4 carbons, or alkylaryl where aryl group is substituted with R.sub.6; or a pharmaceutically acceptable salt thereof, which are useful in treating metabolic disorders related to insulin resistance or hyperglycemia.